Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression

Psychoneuroendocrinology

Volumn 29, Issue 9, 2004, Pages 1101-1108

  Wichniak, Adam ^a,b   Brunner, Hans ^a   Ising, Marcus ^a   Gil, Francisco Pedrosa ^a   Holsboer, Florian ^a   Friess, Elisabeth ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Benzodiazepine withdrawal; Cortisol; Depression; DEX CRH test; Hypothalamic pituitary adrenocortical system

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BROMAZEPAM; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; DIAZEPAM; HYDROCORTISONE; LITHIUM; LORAZEPAM; OXCARBAZEPINE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GABAERGIC SYSTEM; HAMILTON SCALE; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; HYPERHIDROSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RESTLESSNESS; TREMOR; WITHDRAWAL SYNDROME;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; BROMAZEPAM; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; DEXAMETHASONE; DIAZEPAM; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LORAZEPAM; MALE; MIDDLE AGED; PITUITARY-ADRENAL FUNCTION TESTS; PITUITARY-ADRENAL SYSTEM; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 3042687907     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2003.11.004     Document Type: Article

References (45)

1. Adam K., Oswald I. Effects of lormetazepam and of flurazepam on sleep. Br. J. Clin. Pharmacol. 17:1984;531-538
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC
3. Arvat E., Giordano R., Grottoli S., Ghigo E. Benzodiazepines and anterior pituitary function. J Endocrinol. Invest. 25:2002;735-747
4. Arvat E., Maccagno B., Ramunni J., Di Vito L., Giordano R., Gianotti L., Broglio F., Camanni F., Ghigo E. The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. J Clin. Endocrinol. Metab. 84:1999;2611-2615
5. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 4:1961;53-63
6. Bschor T., Adli M., Baethge C., Eichmann U., Ising M., Uhr M., Modell S., Kunzel H., Muller-Oerlinghausen B., Bauer M. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology. 27:2002;470
7. Busto U.E., Sykora K., Sellers E.M. A clinical scale to assess benzodiazepine withdrawal. J Clin. Psychopharmacol. 9:1989;412-416
8. Christensen P., Lolk A., Gram L.F., Kragh-Sorensen P. Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 106:1992;511-516
9. Christensen P., Lolk A., Gram L.F., Kragh-Sorensen P., Pedersen O.L., Nielsen S. Cortisol and treatment of depression: predictive value of spontaneous and suppressed cortisol levels and course of spontaneous plasma cortisol. Psychopharmacology (Berl). 97:1989;471-475
10. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 1988;Erlbaum, Hillsdale
11. Ehlers C.L., Somes C., Seifritz E., Rivier J.E. CRF/NPY interactions: a potential role in sleep dysregulation in depression and anxiety. Depress. Anxiety. 6:1997;1-9
12. Furukawa T.A., Streiner D.L., Young L.T. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J. Affect. Disord. 65:2001;173-177
13. Furukawa T.A., Streiner D.L., Young L.T. Antidepressant and benzodiazepine for major depression. Cochrane. Database. Syst. Rev. 1:2002;CD001026
14. Gram L.F., Christensen P. Benzodiazepine suppression of cortisol secretion: a measure of anxiolytic activity? Pharmacopsychiatry. 19:1986;19-22
15. Grottoli S., Giordano R., Maccagno B., Pellegrino M., Ghigo E., Arvat E. The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J. Clin. Endocrinol. Metab. 87:2002;4616-4620
16. Grottoli S., Maccagno B., Ramunni J., Di Vito L., Giordano R., Gianotti L., DeStefanis S., Camanni F., Ghigo E., Arvat E. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J. Endocrinol. Invest. 25:2002;420-425
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62
18. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., Chalmers D.T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71:1997;15-21
19. Heuser I., Yassouridis A., Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J. Psychiatr. Res. 28:1994;341-356
20. Heuser I.J., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Yassouridis A., Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am. J. Psychiatry. 153:1996;93-99
21. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501
22. Holsboer F., von Bardeleben U., Steiger A. Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. Neuroendocrinology. 48:1988;32-38
23. Holsboer F., von Bardeleben U., Wiedemann K., Muller O.A., Stalla G.K. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol. Psychiatry. 22:1987;228-234
24. Kalogeras K.T., Calogero A.E., Kuribayiashi T., Khan I., Gallucci W.T., Kling M.A., Chrousos G.P., Gold P.W. In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. J. Clin. Endocrinol. Metab. 70:1990;1462-1471
25. Keck M.E., Welt T., Muller M.B., Landgraf R., Holsboer F. The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin and testosterone secretion in rats. Pharmacopsychiatry. 36:2003;27-31
26. Keck M.E., Welt T., Wigger A., Renner U., Engelmann M., Holsboer F., Landgraf R. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur. J. Neurosci. 13:2001;373-380
27. Keck M.E., Wigger A., Welt T., Muller M.B., Gesing A., Reul J.M., Holsboer F., Landgraf R., Neumann I.D. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology. 26:2002;94-105
28. Liebsch G., Landgraf R., Gerstberger R., Probst J.C., Wotjak C.T., Engelmann M., Holsboer F., Montkowski A. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59:1995;229-239
29. Mellman T.A., Uhde T.W. Withdrawal syndrome with gradual tapering of alprazolam. Am. J. Psychiatry. 143:1986;1464-1466
30. Modell S., Yassouridis A., Huber J., Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology. 65:1997;216-222
31. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389
32. Nickel T., Sonntag A., Schill J., Zobel A.W., Ackl N., Brunnauer A., Murck H., Ising M., Yassouridis A., Steiger A., Zihl J., Holsboer F. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J. Clin. Psychopharmacol. 23:2003;155-168
33. Nijsen M.J., Croiset G., Stam R., Bruijnzeel A., Diamant M., de Wied D., Wiegant V.M. The role of the CRH type 1 receptor in autonomic responses to corticotropin- releasing hormone in the rat. Neuropsychopharmacology. 22:2000;388-399
34. Owens M.J., Vargas M.A., Knight D.L., Nemeroff C.B. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J. Pharmacol. Exp. Ther. 258:1991;349-356
35. Owens M.J., Vargas M.A., Nemeroff C.B. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: implications for a role for CRF in the pathogenesis of anxiety disorders. J. Psychiatr. Res. 27:(suppl. 1):1993;209-220
36. Rohrer T., von R.V., Schulz C., Beyer J., Lehnert H. The stress-, but not corticotropin-releasing hormone-induced activation of the pituitary-adrenal axis in man is blocked by alprazolam. Horm. Metab. Res. 26:1994;200-206
37. Schweizer E., Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr. Scand. Suppl. 393:1998;95-101
38. Skelton K.H., Nemeroff C.B., Knight D.L., Owens M.J. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J. Neurosci. 20:2000;1240-1248
39. Skutella T., Criswell H., Moy S., Probst J.C., Breese G.R., Jirikowski G.F., Holsboer F. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat. Neuroreport. 5:1994;2181-2185
40. Skutella T., Montkowski A., Stohr T., Probst J.C., Landgraf R., Holsboer F., Jirikowski G.F. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol. Neurobiol. 14:1994;579-588
41. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19:1998;162-166
42. van Gaalen M.M., Stenzel-Poore M.P., Holsboer F., Steckler T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur. J. Neurosci. 15:2002;2007-2015
43. von Bardeleben U., Holsboer F., Stalla G.K., Muller O.A. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci. 37:1985;1613-1618
44. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J. Psychiatr. Res. 35:2001;83-94
45. Zobel A.W., Yassouridis A., Frieboes R.M., Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am. J. Psychiatry. 156:1999;949-951